Navigation Links
SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
Date:11/7/2007

Inhibition Was Sustained and Dose-Dependent in Sub-Analysis of Phase II

TRA- PCI Trial

ORLANDO, Fla., Nov. 7 /PRNewswire-FirstCall/ -- SCH 530348 (TRA), the novel investigational antiplatelet agent in development by Schering-Plough Corporation (NYSE: SGP), was shown to be a potent inhibitor of platelet aggregation in a sub-analysis of the Thrombin Receptor Antagonist - Percutaneous Coronary Intervention (TRA-PCI) trial presented today at the American Heart Association Scientific Sessions.

The pharmacokinetic and pharmacodynamic analysis, conducted by the University of Tennessee Health Science Center, Memphis, showed that SCH 530348 (TRA), a potent thrombin receptor antagonist, demonstrated sustained, dose- dependent, specific agonist-induced inhibition of platelet aggregation in blood samples from patients undergoing non-urgent percutaneous coronary intervention (PCI).

"The inhibition of platelet aggregation plays a critical role in reducing the formation of deleterious blood clots in patients undergoing PCI," said Lisa K. Jennings, Ph.D., FAHA, Professor, Department of Medicine; Director, Vascular Biology Center of Excellence, University of Tennessee Health Science Center, Memphis, TN; and lead author. "TRA's potentially unique mechanism of action inhibits platelet aggregation through a different pathway from other antiplatelet agents currently available," added Jennings.

"Despite recent advances in cardiovascular care, current levels of morbidity and mortality make it clear that an unmet medical need exists for patients with acute coronary syndromes and those at risk of atherothrombosis. We believe these results add to the evidence indicating that TRA may be a p
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014  Zebra Imaging, ... visualization technologies announced today a strategic partnership with ... in high-end 3D anatomy and biomedical models for ... and medical education markets.  Zygote maintains the world,s ... biomedical models and has pioneered development of high-end ...
(Date:10/31/2014)... JERUSALEM , October 31, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... the company will host a conference call to ... clinical trial of ORMD-0801, the company,s proprietary oral ... Monday, November 3, 2014 at 10:00 a.m. Eastern ...
(Date:10/31/2014)... 31, 2014  Zacks.com announces the list of stocks featured in ... the latest news and events impacting stocks and the financial markets. ... AMGN - Free Report ), Celgene (Nasdaq: CELG ... - Free Report ), Market Vectors Biotech ETF (AMEX: ... ETF (AMEX: XBI - Free Report ). ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... Oritavancin Studies Presented at ECCMID/ICC, MUNICH, Germany, ... announced results from two studies showing the,improved ... in vitro,when tested with a common wetting ... activity of oritavancin against S.,pneumoniae in a ...
... 04, 2007 /PRNewswire-FirstCall/ -- Celgene,Corporation announced that ... that its Data Monitoring Committee's (DMC),review of ... for patients with newly diagnosed multiple myeloma ... dose of dexamethasone (Decadron) in,combination with lenalidomide ...
Cached Medicine Technology:Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7
(Date:10/31/2014)... Santa Barbara, CA (PRWEB) October 31, 2014 ... for holiday shoppers to find affordable but tasteful gifts for ... special 22nd Annual Early Bird Gift Giving Special , ... percent off when they purchase Wine Club Gift membership. ... to take advantage of this special. Besides offering discounts, Gold ...
(Date:10/31/2014)... 2014 The Suspension Revolution review published ... was developed by Dan Long, a suspension training specialist. ... fitness professional and life coach. The author of this ... muscles is not impossible , The Suspension Revolution review ... Suspension training promises efficiency when it comes to burning ...
(Date:10/31/2014)... October 31, 2014 North Shore Eye ... Garden City, Long Island and the addition of leading ... staff, according to North Shore Eye Care Medical Director, ... Acting Chairman of the Department of Ophthalmology of Winthrop-University ... in Garden City for more than 30 years. He ...
(Date:10/31/2014)... Beach, Florida (PRWEB) October 31, 2014 ... or, the “Company”) today announced it has signed a ... Canada-based companies in the urban cultivation sector - Urban ... (BC Northern Lights”), and W3 Metal Inc. (“W3 Metal” ... the “Target Companies”). Pursuant to the LOI and ...
(Date:10/31/2014)... RESEARCH UK scientists have found a drug combination that ... - paving the way for new treatments, according to ... Research Institute (NCRI) Cancer Conference in Liverpool next week*. ... initiate a chain of events culminating in self destruction. ... and become immortal. This means that cells grow out ...
Breaking Medicine News(10 mins):Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... cancer of the eye need not have to remove their ... The results of the Collaborative ocular Melanoma ... found that survival rates were the same regardless of whether ... radiation therapy.// , Davidorf, Professor ...
... affects women in their 30s and 40s, especially women.The illness ... cause pain, inflammation and joint destruction. , ... condition, but one third of the patients discontinue treatment early ... taking Methotrexate are prone for their drug-related liver damage .This ...
... exercise can improve their health or it would not make a ... Consensus statements published by the American College of ... researchers often can't tell how much health-improvement pay-off will result from ... make a difference at all. , , ...
... levels is becoming an increasingly important part of a medical ... or 'good' cholesterol) levels should be high, and low density ... At Johns Hopkins ... to measure non-HDL cholesterol too. This is the difference between ...
... to kill the deadly Hepatitis E virus has been designed by ... would kill the virus by cutting RNA. , , ... animals. The cloned virus could also be used for diagnostic purposes ... For this, the team had produced ...
... in tomato products, such as tomato sauce and ketchup, have ... especially prostate cancer, but the reason for such an action ... that lycopene, which is found in tomato products and other ... and treating the disease in its earliest stages.// ...
Cached Medicine News:Health News:How much can exercise improve health? 2Health News:Protective effects of tomatoes in prostate cancer 2
A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
... L.E.D. is mounted coaxially on the loupe ... battery pack giving 4 hours continuous use. ... and a charging unit that can hold ... as being a convenient container to keep ...
The PDM utilizes the latest technology for measuring interpupillary distance and left/right pupil-to-nose distance. Lightweight and easy-to-use, the PDM provides accurate and repeatable PD measuremen...
Inquire...
Medicine Products: